ABCL
Neutral signal
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Financial indicators Unavailable or mixed. Current ratio 11.32 · operating margin -289% — readings disagree
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Unavailable or mixed. No stored price series
ACHAT TOTAL: 37200 titres (~383904 USD)
- Insiders
- Booth Andrew
- Total bought
-
$383,904
Avg buy (VWAP, 90d window) $10.47 vs last close —
- Total sold
-
—
Avg sell (VWAP, 90d window) —
- Last activity
- 2026-08-14
- Last synced
-
2026-08-15 10:30:23
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-08-18 | Montalbano John S. | Buy | 10,000 | $11.03 | $110,300 | Form 4 |
| 2026-08-14 | Booth Andrew | Buy | 37,200 | $10.32 | $383,904 | Form 4 |
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Market snapshot
Signal
Neutral signalScored 2026-09-06
ABCL presents a deeply conflicted setup: while the Phase 2 ABCL635 catalyst and insider buy provide a moderate event-driven signal, the company's severe operational distress — negative margins, extreme cash burn, and a…
The first sentence of the analysis written for ABCL on 2026-09-06 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 61.6% | 100.0% | 100.0% | 86.3% | 87.9% | |
| Ebit Margin | -236.4% | -1044.4% | -586.6% | 46.8% | 59.1% | |
| Ebitda Margin | -198.0% | -708.0% | -505.3% | 53.6% | 63.7% | |
| Operating Profit Margin | -289.0% | -1091.7% | -623.8% | 44.6% | 54.5% | |
| Pretax Profit Margin | -236.4% | -695.0% | -457.7% | 49.3% | 58.4% | |
| Continuous Operations Profit Margin | -194.9% | -564.8% | -385.0% | 32.7% | 40.9% | |
| Net Profit Margin | -194.9% | -564.8% | -385.0% | 32.7% | 40.9% | |
| Bottom Line Profit Margin | -194.9% | -564.8% | -385.0% | 32.7% | 40.9% | |
| Current Ratio | 11.324 | 9.807 | 7.327 | 8.667 | 7.705 | |
| Quick Ratio | 11.226 | 9.807 | 7.318 | 8.654 | 7.691 | |
| Solvency Ratio | -0.301 | -0.216 | -0.344 | 0.623 | 0.583 | |
| Cash Ratio | 1.998 | 2.040 | 1.120 | 3.267 | 3.946 | |
| Price To Earnings Ratio | -6.980 | -5.327 | -11.196 | 18.089 | 25.536 | |
| Price To Earnings Growth Ratio | 0.640 | -0.679 | 0.059 | 0.000 | 0.340 | |
| Forward Price To Earnings Growth Ratio | 0.640 | -0.679 | 0.059 | 0.000 | 0.340 | |
| Price To Earnings Diluted Ratio | -6.980 | -5.327 | -11.196 | 20.260 | 29.792 | |
| Price To Earnings Diluted Growth Ratio | 0.640 | -0.679 | 0.055 | 4.862 | 4.469 | |
| Price To Book Ratio | 1.057 | 0.817 | 1.433 | 2.341 | 3.844 | |
| Price To Sales Ratio | 13.598 | 29.909 | 43.423 | 5.949 | 10.510 | |
| Price To Free Cash Flow Ratio | -5.869 | -4.613 | -13.603 | 14.107 | 21.186 | |
| Price To Operating Cash Flow Ratio | -7.781 | -7.944 | -37.631 | 10.411 | 16.123 | |
| Debt To Assets Ratio | 0.106 | 0.048 | 0.052 | 0.053 | 0.030 | |
| Debt To Equity Ratio | 0.148 | 0.062 | 0.067 | 0.067 | 0.039 | |
| Debt To Capital Ratio | 0.129 | 0.058 | 0.063 | 0.063 | 0.038 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.403 | 1.288 | 1.291 | 1.249 | 1.285 | |
| Working Capital Turnover Ratio | 0.112 | 0.040 | 0.046 | 0.566 | 0.494 | |
| Operating Cash Flow Ratio | -2.042 | -1.417 | -0.369 | 2.344 | 2.027 | |
| Operating Cash Flow Sales Ratio | -1.748 | -3.765 | -1.154 | 0.571 | 0.652 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.326 | 1.722 | 2.766 | 0.738 | 0.761 | |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 | 44.397 | 33.199 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 53.526 | 39.122 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -0.917 | -1.661 | -0.567 | 3.372 | 6.105 | |
| Capital Expenditure Coverage Ratio | -3.070 | -1.385 | -0.566 | 3.817 | 4.184 | |
| Dividend Paid And Capex Coverage Ratio | -3.070 | -1.385 | -0.566 | 3.817 | 4.184 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -6.965 | -3.779 | -8.302 | 9.930 | 14.666 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 61.6% | ▼-38.4% | ▼-25.5% |
| Ebit Margin | -236.4% | ▲808.1% | ▲115.9% |
| Ebitda Margin | -198.0% | ▲510.0% | ▲60.8% |
| Operating Profit Margin | -289.0% | ▲802.7% | ▲92.1% |
| Pretax Profit Margin | -236.4% | ▲458.6% | ▲19.9% |
| Continuous Operations Profit Margin | -194.9% | ▲369.9% | ▲19.4% |
| Net Profit Margin | -194.9% | ▲369.9% | ▲19.4% |
| Bottom Line Profit Margin | -194.9% | ▲369.9% | ▲19.4% |
| Current Ratio | 11.324 | ▲1.517 | ▲2.358 |
| Quick Ratio | 11.226 | ▲1.418 | ▲2.287 |
| Solvency Ratio | -0.301 | ▼-0.085 | ▼-0.370 |
| Cash Ratio | 1.998 | ▼-0.042 | ▼-0.476 |
| Price To Earnings Ratio | -6.980 | ▼-1.652 | ▼-11.004 |
| Price To Earnings Growth Ratio | 0.640 | ▲1.319 | ▲0.568 |
| Forward Price To Earnings Growth Ratio | 0.640 | ▲1.319 | ▲0.568 |
| Price To Earnings Diluted Ratio | -6.980 | ▼-1.652 | ▼-12.289 |
| Price To Earnings Diluted Growth Ratio | 0.640 | ▲1.319 | ▼-1.230 |
| Price To Book Ratio | 1.056 | ▲0.240 | ▼-0.842 |
| Price To Sales Ratio | 13.598 | ▼-16.312 | ▼-7.080 |
| Price To Free Cash Flow Ratio | -5.869 | ▼-1.256 | ▼-8.111 |
| Price To Operating Cash Flow Ratio | -7.781 | ▲0.163 | ▼-2.416 |
| Debt To Assets Ratio | 0.105 | ▲0.058 | ▲0.048 |
| Debt To Equity Ratio | 0.148 | ▲0.086 | ▲0.071 |
| Debt To Capital Ratio | 0.129 | ▲0.071 | ▲0.059 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.403 | ▲0.115 | ▲0.100 |
| Working Capital Turnover Ratio | 0.112 | ▲0.072 | ▼-0.139 |
| Operating Cash Flow Ratio | -2.042 | ▼-0.625 | ▼-2.150 |
| Operating Cash Flow Sales Ratio | -1.748 | ▲2.017 | ▼-0.659 |
| Free Cash Flow Operating Cash Flow Ratio | 1.326 | ▼-0.396 | ▼-0.137 |
| Debt Service Coverage Ratio | 0.000 | 0.000 | ▼-15.519 |
| Interest Coverage Ratio | 0.000 | 0.000 | ▼-18.529 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | -0.917 | ▲0.744 | ▼-2.183 |
| Capital Expenditure Coverage Ratio | -3.070 | ▼-1.685 | ▼-3.666 |
| Dividend Paid And Capex Coverage Ratio | -3.070 | ▼-1.685 | ▼-3.666 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -6.965 | ▼-3.187 | ▼-8.075 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $1.02B | $862.4M | $1.65B | $2.89B | $3.94B | |
| Enterprise value | $1.04B | $771.4M | $1.60B | $2.58B | $3.51B | |
| EV / Sales | 13.79x | 26.75x | 41.95x | 5.32x | 9.35x | |
| EV / Op. cash flow | -7.89x | -7.11x | -36.36x | 9.31x | 14.34x | |
| EV / Free cash flow | -5.95x | -4.13x | -13.14x | 12.62x | 18.84x | |
| EV / EBITDA | -6.96x | -3.78x | -8.30x | 9.93x | 14.67x | |
| Net debt / EBITDA | -0.10x | 0.45x | 0.29x | -1.17x | -1.82x | |
| Current ratio | 11.32x | 9.81x | 7.33x | 8.67x | 7.71x | |
| Income quality | 0.90x | 0.67x | 0.30x | 1.75x | 1.59x | |
| Graham number | — | — | — | $7 | $7 | |
| Graham net-net | $1 | $1 | $2 | $2 | $2 | |
| Tax burden | 82.4% | 81.3% | 84.1% | 66.3% | 70.0% | |
| Interest burden | 100.0% | 66.5% | 78.0% | 105.3% | 98.8% | |
| Working capital | $663.9M | $674.8M | $753.0M | $907.2M | $809.1M | |
| Invested capital | $1.18B | $1.11B | $1.21B | $1.30B | $1.12B | |
| Return on assets | -10.8% | -12.0% | -9.8% | 10.3% | 11.6% | |
| Operating ROA | -16.0% | -22.1% | -15.7% | 15.1% | 17.6% | |
| Return on tangible assets | -11.5% | -12.8% | -11.1% | 11.6% | 13.7% | |
| Return on equity | -15.1% | -15.4% | -12.7% | 12.9% | 15.0% | |
| Return on invested capital | -13.8% | -19.9% | -14.5% | 10.1% | 11.9% | |
| Return on capital employed | -16.8% | -24.5% | -17.3% | 15.2% | 17.1% | |
| Earnings yield | -14.3% | -18.9% | -8.9% | 5.5% | 3.9% | |
| Free cash flow yield | -17.0% | -21.7% | -7.4% | 7.1% | 4.7% | |
| Capex / Op. cash flow | -32.6% | -72.2% | -176.6% | 26.2% | 23.9% | |
| Capex / Depreciation | 192.9% | 80.8% | 250.9% | 219.5% | 338.9% | |
| Capex / Sales | 56.9% | 271.9% | 203.8% | 15.0% | 15.6% | |
| SG&A / Sales | 101.9% | 296.5% | 197.7% | 13.8% | 13.0% | |
| R&D / Sales | 248.7% | 580.1% | 462.0% | 22.2% | 16.5% | |
| Stock comp / Sales | 74.3% | 234.4% | 168.8% | 10.2% | 8.2% | |
| Intangibles / Total assets | 6.4% | 6.6% | 11.3% | 11.6% | 14.9% | |
| Days sales outstanding | 745d | 1166d | 618d | 78d | 170d | |
| Days payables outstanding | 319d | 0d | 0d | 81d | 120d | |
| Operating cycle | 826d | 1166d | 618d | 86d | 184d | |
| Cash conversion cycle | 506d | 1166d | 618d | 5d | 64d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+18.5%EV / Sales ▼-48.4%EV / EBITDA ▼-84.3%EV / Op. cash flow ▼-0.787Earnings yield ▲+0.046
Profitability
Return on equity ▲+0.003Return on assets ▲+0.012Return on invested capital ▲+0.061Return on capital employed ▲+0.077Operating ROA ▲+0.061Income quality ▲+0.230Tax burden ▲+0.012
Efficiency
Days sales outstanding ▼-421.009Days payables outstanding n/aOperating cycle ▼-340.767Cash conversion cycle ▼-660.264Capex / Sales ▼-2.150R&D / Sales ▼-3.314
Balance-sheet strength
Current ratio ▲+1.517Net debt / EBITDA ▼-0.544Working capital ▼-10833000.000Invested capital ▲+73009000.000Intangibles / Total assets ▼-0.003
Change over 5 years
Valuation
Market cap ▼-74.1%EV / Sales ▲+47.6%EV / EBITDA ▼-147.5%EV / Op. cash flow ▼-22.233Earnings yield ▼-0.182
Profitability
Return on equity ▼-0.301Return on assets ▼-0.224Return on invested capital ▼-0.257Return on capital employed ▼-0.339Operating ROA ▼-0.336Income quality ▼-0.697Tax burden ▲+0.124
Efficiency
Days sales outstanding ▲+575.172Days payables outstanding ▲+199.819Operating cycle ▲+642.005Cash conversion cycle ▲+442.186Capex / Sales ▲+0.414R&D / Sales ▲+2.321
Balance-sheet strength
Current ratio ▲+3.619Net debt / EBITDA ▲+1.725Working capital ▼-145199000.000Invested capital ▲+61177000.000Intangibles / Total assets ▼-0.085
Employee count
Peer market caps
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent news
- 2026-08-13 AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants.
- 2026-08-12 What''s Going on With AbCellera Biologics Stock On Wednesday? AbCellera Biologics Inc. (NASDAQ:ABCL) shares are trading higher on Wednesday following the announcement of positive Phase 2 clinical trial results for ABCL635, a single-dose treatment aimed at alleviating menopausal hot flashes.
- 2026-08-11 AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants.
- 2026-08-11 Investors Buy Large Volume of AbCellera Biologics Call Options (NASDAQ:ABCL) AbCellera Biologics Inc. (NASDAQ: ABCL - Get Free Report) was the target of unusually large options trading on Monday. Stock investors purchased 16,666 call options on the company. This is an increase of approximately 151% compared to the typical daily volume of 6,636 call options. AbCellera Biologics News Roundup Here are the key news stories impacting
- 2026-08-10 AbCellera Biologics Inc. (ABCL) Discusses Phase II Top Line Results for ABCL635 in Treatment of Moderate-to-Severe Hot Flashes Transcript AbCellera Biologics Inc. (ABCL) Discusses Phase II Top Line Results for ABCL635 in Treatment of Moderate-to-Severe Hot Flashes Transcript
- 2026-08-10 AbCellera Biologics Menopause Drug Data Shows ''New Efficacy Benchmark'' AbCellera Biologics Inc. (NASDAQ:ABCL) announced positive top-line Phase 2 results from its Phase 1/2 trial evaluating ABCL635.
- 2026-08-10 AbCellera Stock Jumps 33% on a Positive Menopause Trial AbCellera (ABCL), a Vancouver clinical-stage antibody biotech, rose 33.19% intraday after its experimental menopause drug ABCL635 met both primary goals in a Ph
- 2026-08-10 AbCellera''s ABCL-635 Cuts Menopause Hot Flashes 83% in Phase II Trial AbCellera Biologics NASDAQ: ABCL reported top-line four-week results from a Phase II trial of ABCL-635, an investigational non-hormonal treatment for moderate to severe vasomotor symptoms, or hot flashes, associated with menopause.
- 2026-08-10 AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profi [url="]AbCellera[/url] (Nasdaq: ABCL) today announced positive top-line results from the Phase 2 portion of its Phase 1/2 clinical trial evaluating ABCL635, an
- 2026-08-10 AbCellera menopause drug cuts hot flashes in mid-stage trial, shares rise AbCellera said Monday its experimental menopause treatment significantly reduced the frequency and severity of hot flashes in a mid-stage trial, sending its shares up 24% in premarket trading.